BGV V is a EUR 150 million fund and was launched in March 2023. We are actively looking for new seed and early stage investment opportunities in biotech companies for the BGV V Fund. …

We are a venture capital firm specialised in seed investment for innovative early stage companies. BGV generally acts as lead investor. Our team is made up of life science experts and business …

Jul 13, 2023 · BGV V will build on the successful investment strategy of previous BGV funds: dedication to early-stage ventures and company creation and seeking out therapeutic …

BGV V Apply filters Currently in our portfolio. Artica Therapeutics. Artica uses the power of covalent chemistry to develop novel therapies for autoimmune and inflammatory disorders. …

BioGeneration Ventures (BGV) is the early-stage strategy of the Forbion-BGV platform of funds, which also includes Forbion Ventures and Forbion Growth. BGV is located with Forbion in …

BGV IV is a EUR 140 million fund and was launched in April 2020. The portfolio was completed in March 2023 with twelve portfolio investments.

Shaping new life-science ventures. Newsletter. Subscribe to our news releases. Subscribe

Nov 2, 2023 · The round was co-led by Thuja Capital and Seroba, with participation from InnovationQuarter and founding investor BGV. Proceeds from the financing will be used to …

Jul 13, 2023 · Endpoints News interviewed Managing Partner Edward van Wezel about the company's final close for BGV Fund V. Read the interview here.

Mar 21, 2024 · LEIDEN, The Netherlands – March 21, 2024 – Artica Therapeutics B.V. (Artica), a biotechnology company developing a pipeline of covalent small molecules for autoimmune and …